11.30

0.13% -0.015

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $11.30, with a volume of 658.45K. It is down -0.13% in the last 24 hours and up +13.05% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$11.32

Open:

$11.38

24h Volume:

658.45K

Relative Volume:

1.05

Market Cap:

$901.72M

Revenue:

$62.71M

Net Income/Loss:

$-112.51M

P/E Ratio:

-7.4868

EPS:

-1.51

Net Cash Flow:

$-96.01M

1W Performance:

-12.77%

1M Performance:

+13.05%

6M Performance:

-32.02%

1Y Performance:

+22.48%

1-Day Range:

$11.00

$12.19

1-Week Range:

$10.86

$13.05

52-Week Range:

$8.21

$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2024-10-31

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	11.30	901.72M	62.71M	-112.51M	-96.01M	-1.51
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

08:49 AM